IL2 and multiple sclerosis: However, in experimental models of multiple sclerosis, fenofibrate reduced expression of IL-2, IL-6 and key Toll-like receptor signaling components (including CD14), thereby decreasing microglial activation and pro-inflammatory mediator secretion [93].